Pancreatic cancer

From state-of-the-art treatments to promising novel therapies

Ignacio Garrido-Laguna, Manuel Hidalgo

Research output: Contribution to journalArticle

Abstract

Pancreatic cancer is expected to be the second deadliest malignancy in the USA by 2020. The survival rates for patients with other gastrointestinal malignancies have increased consistently during the past 30 years; unfortunately, however, the outcomes of patients with pancreatic cancer have not changed significantly. Although surgery remains the only curative treatment for pancreatic cancer, therapeutic strategies based on initial resection have not substantially improved the survival of patients with resectable disease over the past 25 years; presently, more than 80% of patients suffer disease relapse after resection. Preclinical evidence that pancreatic cancer is a systemic disease suggests a possible benefit for early administration of systemic therapy in these patients. In locally advanced disease, the role of chemoradiotherapy is increasingly being questioned, particularly considering the results of the LAP-07 trial. Novel biomarkers are clearly needed to identify subsets of patients likely to benefit from chemoradiotherapy. In the metastatic setting, FOLFIRINOX (folinic acid, 5-fluorouracil, irinotecan, and oxaliplatin), and nab-paclitaxel plus gemcitabine have yielded only modest improvements in survival. Thus, new treatments are urgently needed for patients with pancreatic cancer. Herein, we review the state-of-the-art of pancreatic cancer treatment, and the upcoming novel therapeutics that hold promise in this disease are also discussed.

Original languageEnglish (US)
Pages (from-to)319-334
Number of pages16
JournalNature Reviews Clinical Oncology
Volume12
Issue number6
DOIs
StatePublished - Jun 30 2015
Externally publishedYes

Fingerprint

Pancreatic Neoplasms
oxaliplatin
irinotecan
Chemoradiotherapy
gemcitabine
Therapeutics
Survival
Second Primary Neoplasms
Leucovorin
Fluorouracil
Survival Rate
Biomarkers
Recurrence
Neoplasms

ASJC Scopus subject areas

  • Oncology

Cite this

Pancreatic cancer : From state-of-the-art treatments to promising novel therapies. / Garrido-Laguna, Ignacio; Hidalgo, Manuel.

In: Nature Reviews Clinical Oncology, Vol. 12, No. 6, 30.06.2015, p. 319-334.

Research output: Contribution to journalArticle

Garrido-Laguna, Ignacio ; Hidalgo, Manuel. / Pancreatic cancer : From state-of-the-art treatments to promising novel therapies. In: Nature Reviews Clinical Oncology. 2015 ; Vol. 12, No. 6. pp. 319-334.
@article{016eacb4d548479699a914ecd8a43455,
title = "Pancreatic cancer: From state-of-the-art treatments to promising novel therapies",
abstract = "Pancreatic cancer is expected to be the second deadliest malignancy in the USA by 2020. The survival rates for patients with other gastrointestinal malignancies have increased consistently during the past 30 years; unfortunately, however, the outcomes of patients with pancreatic cancer have not changed significantly. Although surgery remains the only curative treatment for pancreatic cancer, therapeutic strategies based on initial resection have not substantially improved the survival of patients with resectable disease over the past 25 years; presently, more than 80{\%} of patients suffer disease relapse after resection. Preclinical evidence that pancreatic cancer is a systemic disease suggests a possible benefit for early administration of systemic therapy in these patients. In locally advanced disease, the role of chemoradiotherapy is increasingly being questioned, particularly considering the results of the LAP-07 trial. Novel biomarkers are clearly needed to identify subsets of patients likely to benefit from chemoradiotherapy. In the metastatic setting, FOLFIRINOX (folinic acid, 5-fluorouracil, irinotecan, and oxaliplatin), and nab-paclitaxel plus gemcitabine have yielded only modest improvements in survival. Thus, new treatments are urgently needed for patients with pancreatic cancer. Herein, we review the state-of-the-art of pancreatic cancer treatment, and the upcoming novel therapeutics that hold promise in this disease are also discussed.",
author = "Ignacio Garrido-Laguna and Manuel Hidalgo",
year = "2015",
month = "6",
day = "30",
doi = "10.1038/nrclinonc.2015.53",
language = "English (US)",
volume = "12",
pages = "319--334",
journal = "Nature Clinical Practice Oncology",
issn = "1759-4774",
publisher = "Nature Publishing Group",
number = "6",

}

TY - JOUR

T1 - Pancreatic cancer

T2 - From state-of-the-art treatments to promising novel therapies

AU - Garrido-Laguna, Ignacio

AU - Hidalgo, Manuel

PY - 2015/6/30

Y1 - 2015/6/30

N2 - Pancreatic cancer is expected to be the second deadliest malignancy in the USA by 2020. The survival rates for patients with other gastrointestinal malignancies have increased consistently during the past 30 years; unfortunately, however, the outcomes of patients with pancreatic cancer have not changed significantly. Although surgery remains the only curative treatment for pancreatic cancer, therapeutic strategies based on initial resection have not substantially improved the survival of patients with resectable disease over the past 25 years; presently, more than 80% of patients suffer disease relapse after resection. Preclinical evidence that pancreatic cancer is a systemic disease suggests a possible benefit for early administration of systemic therapy in these patients. In locally advanced disease, the role of chemoradiotherapy is increasingly being questioned, particularly considering the results of the LAP-07 trial. Novel biomarkers are clearly needed to identify subsets of patients likely to benefit from chemoradiotherapy. In the metastatic setting, FOLFIRINOX (folinic acid, 5-fluorouracil, irinotecan, and oxaliplatin), and nab-paclitaxel plus gemcitabine have yielded only modest improvements in survival. Thus, new treatments are urgently needed for patients with pancreatic cancer. Herein, we review the state-of-the-art of pancreatic cancer treatment, and the upcoming novel therapeutics that hold promise in this disease are also discussed.

AB - Pancreatic cancer is expected to be the second deadliest malignancy in the USA by 2020. The survival rates for patients with other gastrointestinal malignancies have increased consistently during the past 30 years; unfortunately, however, the outcomes of patients with pancreatic cancer have not changed significantly. Although surgery remains the only curative treatment for pancreatic cancer, therapeutic strategies based on initial resection have not substantially improved the survival of patients with resectable disease over the past 25 years; presently, more than 80% of patients suffer disease relapse after resection. Preclinical evidence that pancreatic cancer is a systemic disease suggests a possible benefit for early administration of systemic therapy in these patients. In locally advanced disease, the role of chemoradiotherapy is increasingly being questioned, particularly considering the results of the LAP-07 trial. Novel biomarkers are clearly needed to identify subsets of patients likely to benefit from chemoradiotherapy. In the metastatic setting, FOLFIRINOX (folinic acid, 5-fluorouracil, irinotecan, and oxaliplatin), and nab-paclitaxel plus gemcitabine have yielded only modest improvements in survival. Thus, new treatments are urgently needed for patients with pancreatic cancer. Herein, we review the state-of-the-art of pancreatic cancer treatment, and the upcoming novel therapeutics that hold promise in this disease are also discussed.

UR - http://www.scopus.com/inward/record.url?scp=84930182118&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84930182118&partnerID=8YFLogxK

U2 - 10.1038/nrclinonc.2015.53

DO - 10.1038/nrclinonc.2015.53

M3 - Article

VL - 12

SP - 319

EP - 334

JO - Nature Clinical Practice Oncology

JF - Nature Clinical Practice Oncology

SN - 1759-4774

IS - 6

ER -